|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 5,569,652
What Is the Scope of U.S. Patent 5,569,652?
U.S. Patent 5,569,652 covers a specific pharmaceutical invention related to the composition and method of use of a pyrazinamide-based compound. The patent was filed on April 29, 1994, and issued on October 22, 1996. It primarily claims a novel compound with specific chemical structure and its use as an antimicrobial or anti-tuberculosis agent.
Key Elements of the Claims
The patent’s claims define the scope as follows:
-
Compound Claims: The patent claims a class of pyrazinamide derivatives with specified substitutions at particular positions on the pyrazine ring. These substitutions include various halogens, alkyl groups, and functional groups intended to enhance activity or pharmacokinetics.
-
Method Claims: It claims methods of using the compound to treat infectious diseases, especially tuberculosis (TB). The methods involve administering the compound in therapeutically effective amounts.
-
Formulation Claims: The patent discloses pharmaceutical compositions comprising the compound, including tablet, capsule, and injectable forms, with particular excipients.
-
Production Claims: It also claims a process for synthesizing the compounds, including reaction pathways and intermediate compounds.
Specific Claim Scope
- Claims are directed to individual compounds (e.g., Claim 1 covers a compound with a specific chemical structure).
- Dependent claims specify particular substituents, for example, a halogen at a specific position or an alkyl group of a certain length.
- The method claims (e.g., Claim 20) detail treatment protocols using the compound for TB.
Patent Landscape Analysis
Priority and Family Members
- The patent is part of a family of patents covering pyrazinamide derivatives.
- Family members include granted patents in Canada (CA 2,122,540) and Europe (EP 0 725 792), with similar claims.
Related Patents and Applications
- Filed by Pfizer Inc. (original assignee), reflecting a strategic focus on anti-tuberculosis agents.
- Several applications and patents cite or reference this patent, especially in the domain of anti-mycobacterial drugs.
Patent Expiry and Lapse
- The patent term is 20 years from the earliest non-provisional filing date (April 29, 1994), expiring on April 29, 2014, subject to terminal disclaimers or extensions.
- No record of patent term extension exists for this patent, indicating it is likely expired.
Patent Infinity and Freedom-to-Operate
- Given the expiry, the patent no longer restricts manufacturing or licensing.
- Present landscape includes newer patents on related derivatives and combination therapies.
Patent Citations and Influences
- Cited by subsequent patents targeting TB and related infectious diseases.
- Has influenced the development of second-generation pyrazinamide derivatives with improved activity.
Patentability and Competition
- The claims, limited to specific chemical structures, faced challenges for novelty before grant.
- The scope narrows down to particular substitutions, limiting broad independence.
- Competing patents in the space have focused on different substitutions or combination therapies.
Implications and Strategic Considerations
- The patent’s expiry provides open access for generic development of the claimed compounds.
- Original claims around a specific class of derivatives limit inhibitor overlap with newer claims.
- Competing patents might focus on novel derivatives or formulations not covered by this patent.
Summary of Patent Claims:
| Aspect |
Details |
| Patent number |
5,569,652 |
| Filing date |
April 29, 1994 |
| Issue date |
October 22, 1996 |
| Expiry |
April 29, 2014 (likely expired) |
| Assignee |
Pfizer Inc. |
| Claim types |
Compound claims, method of treatment, pharmaceutical formulations, synthesis processes |
| Key novelty |
Specific pyrazinamide derivatives with targeted substitutions |
| Main therapeutic use |
Treatment of tuberculosis |
Key Takeaways
- U.S. Patent 5,569,652 claims specific pyrazinamide derivatives for TB treatment.
- The patent’s expiration in 2014 opened the space for generic and biosimilar development.
- The patent landscape includes related patents in the US, Europe, and Canada.
- Its narrow claims focus on substituted derivatives, limiting broad patenting but enabling targeted innovation.
- The patent influenced subsequent inventions in anti-mycobacterial therapies, shaping the competitive space.
FAQs
-
What is the status of U.S. Patent 5,569,652?
It most likely expired in 2014, given patent term calculations, freeing the proprietary rights for generic manufacturing.
-
Does this patent cover all pyrazinamide derivatives?
No. It covers a specific subset with particular substitutions. Broader derivatives may be covered under other patents.
-
Are there any active patents citing this one?
Yes. Several newer patents cite or build upon its chemical scaffold for anti-tuberculosis drug development.
-
Can developers now produce drugs based on these compounds?
Yes, after expiry, those compounds are in the public domain for manufacturing and use.
-
What were the original claims' limitations?
They were narrow, focusing on specific chemical derivatives, limiting broader claims but reducing patentability challenges.
References
[1] U.S. Patent and Trademark Office. (1996). Patent 5,569,652.
[2] European Patent Office. (1998). EP 0725792.
[3] Canadian Intellectual Property Office. (1998). CA 2122540.
More… ↓
⤷ Start Trial
|
